Advertisement

Topics

Chimeric Therapies Incorporated Company Profile

12:16 EDT 26th September 2017 | BioPortfolio

Chimeric Therapirs Incorporated is committed to developing bone marrow graft engineering to expand the use of safe and effective cellular grafts tailored to treat and cure diseases.

Location

28202 Cabot Road, Suite 210
Laguna Niguel
CA
92677
United States of America

Contact

Phone: 281 851 3035
Fax: 281 361 8463


News Articles [503 Associated News Articles listed on BioPortfolio]

Unleashing CAR-T Therapies on Solid Tumors: Are We There Yet?

Chimeric antigen receptor (CAR) T cell therapies have shown dramatic results against certain blood cancers ...

Following IBMTR model may make CAR-T therapies affordable, says oncologist and data specialist

News on chimeric antigen receptor T-cell (CAR-T) therapies in the last week has added to the immediacy…

Chimeric antigen receptor T-cell therapies for lymphoma

Cell-based immunotherapies are showing great promise in the treatment of even the most treatment-refractory of haematological malignancies. Herein, Jennifer Brudno and James Kochenderfer review the re...

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Chimeric antigen receptor (CAR)-T-cell therapies are showing great promise in the treatment of cancer, particularly B-cell malignancies, but are associated with characteristic, potentially fatal toxic...

Blood and bone marrow therapies grab spotlight at world's top cancer meeting

CHICAGO (Reuters) - Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters ...

Comprehensive in silico allergenicity assessment of novel protein engineered chimeric Cry proteins for safe deployment in crops

Development of chimeric Cry toxins by protein engineering of known and validated proteins is imperative for enhancing the efficacy and broadening the insecticidal spectrum of these genes. Expression o...

ASCO to shine light on CAR-T developments

Pharma companies are beginning to unveil data they will publish at this year's American Society of Clinical Oncology (ASCO) conference – and it looks like CAR-T therapies could take centre stage. N...

FDA Approval of Tisagenlecleucel as CAR-T Therapy for Leukemia

This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the ...

PubMed Articles [896 Associated PubMed Articles listed on BioPortfolio]

Understanding clinical development of chimeric antigen receptor T cell therapies.

In the past decade, many clinical trials with gene- and cell-based therapies (GCTs) have been performed. Increased interest in the development of these drug products by various stakeholders has become...

Neutralized chimeric DNA probe for detection of single nucleotide polymorphism on surface plasmon resonance biosensor.

An implementation of neutralized chimeric DNA oligomer as a probe for sensitive detection of single nucleotide polymorphisms (SNPs) on a surface plasmon resonance imaging sensor is investigated. The c...

Construction of methanol sensing Escherichia coli by the introduction of Paracoccus denitrificans MxaY based chimeric two-component system.

Escherichia coli, which does not have methanol sensing apparatus, was engineered to sense methanol by employing chimeric two-component system (TCS) strategy. A chimeric MxaY/EnvZ (MxaYZ) TCS was const...

PreC and C Regions of Woodchuck Hepatitis Virus Facilitate Persistent Expression of Surface Antigen of Chimeric WHV-HBV Virus in the Hydrodynamic Injection BALB/c Mouse Model.

In the hydrodynamic injection (HI) BALB/c mouse model with the overlength viral genome, we have found that woodchuck hepatitis virus (WHV) could persist for a prolonged period of time (up to 45 weeks)...

Mind-Body Therapies in Cancer: What Is the Latest Evidence?

Many people living with cancer use complementary therapies, and some of the most popular are mind-body therapies (MBTs), including relaxation and imagery, hypnosis, yoga, meditation, tai chi and qigon...

Clinical Trials [1474 Associated Clinical Trials listed on BioPortfolio]

Anti-IL-6 Chimeric Monoclonal Antibody in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others...

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positi...

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, react...

Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

Objectives: The purpose of this study is to evaluate the safety and prognosis of New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T (nCAR19-T) Cells in the treatment of...

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a human...

Companies [824 Associated Companies listed on BioPortfolio]

Chimeric Therapies Incorporated

Chimeric Therapirs Incorporated is committed to developing bone marrow graft engineering to expand the use of safe and effective cellular grafts tailored to treat and cure diseases.

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

CARMA Therapeutics Inc.

CARMA TherapeuticsSM is a biotechnology company founded in 2016 to bring the power of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimer...

Nile Therapeutics, Inc.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medica...

Pharmapraxis

Founded in 2008 by the Axis Biotec Brasil™ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....

More Information about "Chimeric Therapies Incorporated" on BioPortfolio

We have published hundreds of Chimeric Therapies Incorporated news stories on BioPortfolio along with dozens of Chimeric Therapies Incorporated Clinical Trials and PubMed Articles about Chimeric Therapies Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chimeric Therapies Incorporated Companies in our database. You can also find out about relevant Chimeric Therapies Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Corporate Database Quicklinks



Searches Linking to this Company Record